MONTREAL, June 15, 2026 /PRNewswire/ -- Vision Marine Technologies Inc. (NASDAQ: VMAR; TSXV: VMAR) ("Vision Marine" or the "Company"), today announced that the Company's...
SUZHOU, China, June 15, 2026 /PRNewswire/ -- This month, Suzhou Anta Scaffolding Engineering Co., Ltd. (Anta Scaffolding), a Chinese scaffolding manufacturer and supplier, announced that...
A High-Protein, Zero-Sugar Snack Made for Strength, Energy, and Life on the GoHOUSTON, June 15, 2026 /PRNewswire/ -- Roundhouse Provisions® Grass-Fed Beef Sticks are officially...
SEOUL, South Korea, June 15, 2026 /PRNewswire/ -- K-beauty skincare brand MIXSOON will host a large-scale offline pop-up event at Koreatown Plaza in Los...
Highlights of the Announced Transaction:Will create a bank holding company with approximately $2.4 billion in assets and 10 branches across Washington, D.C., Virginia, Maryland,...
NEW YORK, June 15, 2026 /PRNewswire/ -- Expert Consumers has released a new in depth review highlighting Experian Boost® and its role in helping people...
MELBOURNE, Australia, June 15, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, announces today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for two patent applications, notably a composition-of-matter patent and method-of-use for its Toll-like receptor 2 (TLR2) therapies.
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL
Asedebart is an investigational monoclonal antibody designed to neutralize excess adrenocorticotropic hormone (ACTH) and reduce downstream cortisol production in Cushing's disease (CD)Urinary free cortisol...
Asedebart is an investigational monoclonal antibody designed to neutralize excess adrenocorticotropic hormone (ACTH) and reduce downstream cortisol production in Cushing's disease (CD)Urinary free cortisol...